Related Experiment Video
Updated: Jun 11, 2026
08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Emerging drugs for Hodgkin's lymphoma
Boris Böll1, Peter Borchmann, Volker Diehl
1Physician of the German Hodgkin Study Group, University of Cologne, Internal Medicine I, Kerpener Strasse 62, Cologne 50937, Germany.
Expert Opinion on Emerging Drugs
|July 16, 2010
Summary
New drugs targeting cell surface and intracellular proteins offer hope for Hodgkin
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Current Hodgkin's lymphoma (HL) treatments, while curative for many, cause significant acute and long-term toxicities.
- There is a critical need for novel therapies for elderly patients and those with relapsed HL post-chemotherapy.
- Emerging treatments aim to mitigate treatment-related complications and improve outcomes in challenging patient populations.
Purpose of the Study:
- To summarize the biological rationale behind novel therapeutic agents for Hodgkin's lymphoma.
- To review early clinical data and trial results for emerging drugs in HL treatment.
- To provide an overview of promising new drug candidates for both first-line and relapsed HL.
Main Methods:
- Review of clinical trials published over the last three decades.
- Inclusion of early results from international conferences.
- Focus on drugs targeting cell surface structures (mAbs, immunotoxins) and intracellular proteins.
Main Results:
- Summary of the biological basis for novel drug development in HL.
- Presentation of preliminary clinical data for emerging therapeutic agents.
- Evidence supporting the potential of new drugs to alter HL treatment paradigms.
Conclusions:
- Several new drugs are under investigation for Hodgkin's lymphoma.
- These novel agents are anticipated to significantly impact treatment strategies for both newly diagnosed and relapsed patients.
- The development of targeted therapies holds promise for improving patient outcomes and reducing treatment-related toxicities.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...